Bevacizumab

بواسطة Kazazi-Hyseni, Filis, Beijnen, Jos H., Schellens, Jan H. M.
منشور في 2010

Trastuzumab

بواسطة Boekhout, Annelies H., Beijnen, Jos H., Schellens, Jan H.M.
منشور في 2011

Protein versus DNA as a marker for peripheral blood mononuclear cell counting

بواسطة Jansen, Robert S., Rosing, Hilde, Schellens, Jan H. M., Beijnen, Jos H.
منشور في 2009

Concise Drug Review: Azacitidine and Decitabine

بواسطة Derissen, Ellen J.B., Beijnen, Jos H., Schellens, Jan H.M.
منشور في 2013

Inhibitors of mTOR

بواسطة Klümpen, Heinz-Josef, Beijnen, Jos H., Gurney, Howard, Schellens, Jan H.M.
منشور في 2010

Part 3: Pharmacogenetic Variability in Phase II Anticancer Drug Metabolism

بواسطة Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
منشور في 2011

Part 4: Pharmacogenetic Variability in Anticancer Pharmacodynamic Drug Effects

بواسطة Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
منشور في 2011

Part 1: Background, Methodology, and Clinical Adoption of Pharmacogenetics

بواسطة Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
منشور في 2011

Part 2: Pharmacogenetic Variability in Drug Transport and Phase I Anticancer Drug Metabolism

بواسطة Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
منشور في 2011

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients

بواسطة Deenen, Maarten J., Cats, Annemieke, Beijnen, Jos H., Schellens, Jan H.M.
منشور في 2013

Lapatinib for Advanced or Metastatic Breast Cancer

بواسطة Opdam, Frans L., Guchelaar, Henk-Jan, Beijnen, Jos H., Schellens, Jan H.M.
منشور في 2012

Concise Drug Review: Pazopanib and Axitinib

بواسطة van Geel, Robin M.J.M., Beijnen, Jos H., Schellens, Jan H.M.
منشور في 2012

Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers

بواسطة van den Broek, Irene, Sparidans, Rolf W., Schellens, Jan H. M., Beijnen, Jos H.
منشور في 2010

Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs

بواسطة Kip, Anke E., Schellens, Jan H. M., Beijnen, Jos H., Dorlo, Thomas P. C.
الحاوية / القاعدة Clin Pharmacokinet (2017)

Treatment Individualization in Colorectal Cancer

بواسطة van Geel, Robin M. J. M., Beijnen, Jos H., Bernards, René, Schellens, Jan H.M.
الحاوية / القاعدة Curr Colorectal Cancer Rep (2015)

BRAF Mutations as Predictive Biomarker for Response to Anti‐EGFR Monoclonal Antibodies

بواسطة van Brummelen, Emilie M. J., de Boer, Anthonius, Beijnen, Jos H., Schellens, Jan H. M.
الحاوية / القاعدة Oncologist (2017)

Letter to the Editor Regarding “A Prospective, Controlled Study of the Botanical Compound Mixture LCS101 for Chemotherapy-Induced Hematological Complications in Breast Cancer” by Y...

بواسطة Mooiman, Kim D., Goey, Andrew K.L., Meijerman, Irma, Beijnen, Jos H., Schellens, Jan H.M.
منشور في 2012

Performance of Methods for Handling Missing Categorical Covariate Data in Population Pharmacokinetic Analyses

بواسطة Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
منشور في 2012

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

بواسطة Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
منشور في 2011

Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges

بواسطة van Brummelen, Emilie M.J., Ros, Willeke, Wolbink, Gertjan, Beijnen, Jos H., Schellens, Jan H.M.
الحاوية / القاعدة Oncologist (2016)